OPT: With all due respect to Endless, a Phase 2b success is bigtime. A fair proportion go on to FDA adoption and that means this stock will rapidly be swallowed by a bigger pharma. As well. AMD is a big deal, so it's not an Orphan Drug. With growing age profiles in advanced countries, it is also a growing problem. OPT is into wet AMD, the most serious form (my late father had it & my next door neighbour has it).Unfortunately, I do not hold OPT and note that a Board member sold nearly 700,000 @ 67c to meet a tax debt (but got 3m options strike 85c ish) only weeks ago.
Really should have posted this on STT thread. OPT is not a DT. Just interested in the disease for genetically obvious reasons.
